Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial

What Was Tested

The paper reports a study of Tirzepatide and Semaglutide, published as a randomized controlled trial.

Data for this post hoc analysis was accessed through the Vivli (Center for Global Clinical Research Data) platform ( https://vivli.org ) with the Vivli ID 00009964.

Who Took Part

According to the abstract, 3 adults were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

The researchers performed a post hoc analysis of the SURPASS-2 trial, a randomised phase 3 study including 1879 adults with type 2 diabetes.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Tirzepatide, Glycated Hemoglobin, Blood Glucose and Gastric Inhibitory Polypeptide.

Author keywords: GLP-1/GIP agonist, Glucagon-like peptide-1 therapies, Post hoc analysis, Semaglutide, Therapeutic goals and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized study of Tirzepatide and Semaglutide in 3 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Diabetologia), a journal based in Germany.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.